Home›Trial›NCT06223958
NCT06223958Phase 3ACTIVE NOT RECRUITING

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Study Summary

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration

Conditions
Neovascular Age-Related Macular Degeneration
Interventions / Drugs
OTX-TKI (axitinib implant)Aflibercept
View on ClinicalTrials.gov ↗
Sponsor
OCUL
Ocular Therapeutix
Ophthalmology
D37/100
Study Details
Enrollment344 participants
Primary Completion—
Lead SponsorOcular Therapeutix, Inc.
Data Retrieved2026-04-11 04:23:15.556961+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 344 participants
Sponsor Catalyst Profile

Ocular Therapeutix (OCUL) is the sponsoring company for this trial. BiotechSign currently grades this company D (37/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

OCUL Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.